Cargando…

Danshao Shugan Granule therapy for non-alcoholic fatty liver disease

BACKGROUND: Danshao Shugan Granules (DSSG), a traditional Chinese medicine (TCM), is given to protect the liver. The objective is to evaluate the mechanisms of the effects of DSSG on non-alcoholic fatty liver disease (NAFLD). METHODS: 260 patients with NAFLD were randomly allocated to positive contr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Hui, Xu, Zhongju, Wang, Qi, Shu, Shi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396766/ https://www.ncbi.nlm.nih.gov/pubmed/35999630 http://dx.doi.org/10.1186/s12944-022-01689-9

Ejemplares similares

Intervention of Shugan Xiaozhi Decoction on Nonalcoholic Fatty Liver Disease via Mediating Gut-Liver Axis
por: Yang, Huili, et al.
Publicado: (2022)

A network pharmacology‐based approach to explore the effects of Chaihu Shugan powder on a non‐alcoholic fatty liver rat model through nuclear receptors
por: Nie, Huan, et al.
Publicado: (2020)

Effects of Shugan Hewei Granule on Depressive Behavior and Protein Expression Related to Visceral Sensitivity in a Rat Model of Nonerosive Reflux Disease
por: Wang, Yi, et al.
Publicado: (2019)

Tandem Mass Tag Analysis of the Effect of the Anterior Cingulate Cortex in Nonerosive Reflux Disease Rats with Shugan Jiangni Hewei Granules Treatment
por: Wang, Tianzuo, et al.
Publicado: (2022)

Extracellular Vesicles in Non-alcoholic Fatty Liver Disease and Alcoholic Liver Disease
por: Wu, Dongqing, et al.
Publicado: (2021)

A Network Pharmacology Approach to Explore the Mechanisms of Shugan Jianpi Formula in Liver Fibrosis
por: Fan, Chang, et al.
Publicado: (2020)

Shugan granule contributes to the improvement of depression‐like behaviors in chronic restraint stress‐stimulated rats by altering gut microbiota
por: Li, Junnan, et al.
Publicado: (2022)

Investigation of the potential mechanism of the Shugan Xiaozhi decoction for the treatment of nonalcoholic fatty liver disease based on network pharmacology, molecular docking and molecular dynamics simulation
por: Yang, Rong, et al.
Publicado: (2022)

Is there an effective therapy available for non-alcoholic fatty liver disease?
por: Di Maso, Vittorio, et al.
Publicado: (2009)

Autophagy in non-alcoholic fatty liver disease and alcoholic liver disease()
por: Khambu, Bilon, et al.
Publicado: (2018)

Non-alcoholic fatty liver disease
por: Sattar, Naveed, et al.
Publicado: (2014)

Non-alcoholic fatty liver disease
por: Neuschwander-Tetri, Brent A.
Publicado: (2017)

Homeostasis of Glucose and Lipid in Non-Alcoholic Fatty Liver Disease
por: Chao, Hsu-Wen, et al.
Publicado: (2019)

Systems pharmacology-based exploration reveals mechanisms of anti-steatotic effects of Jiang Zhi Granule on non-alcoholic fatty liver disease
por: Zheng, Yiyuan, et al.
Publicado: (2018)

Relationship between non-alcoholic fatty liver disease and inflammation in patients with non-alcoholic fatty liver
por: Foroughi, Mehdi, et al.
Publicado: (2016)

Alcohol? Not for Non-alcoholic Fatty Liver Disease Patients
por: Cainelli, Francesca, et al.
Publicado: (2020)

Precision Medicine in Fatty Liver Disease/Non-Alcoholic Fatty Liver Disease
por: Valenzuela-Vallejo, Laura, et al.
Publicado: (2023)

Simultaneous Determination of Five Components of Chaihu-Shugan-San in Beagle Plasma by HPLC-MS/MS and Its Application to a Pharmacokinetic Study after a Single Dose of Chaihu-Shugan-San
por: Zhu, Yong-liang, et al.
Publicado: (2020)

Non-alcoholic fatty liver disease and liver secretome
por: Khan, Muhammad Sohaib, et al.
Publicado: (2022)

Current and emerging pharmacological therapy for non-alcoholic fatty liver disease
por: Eshraghian, Ahad
Publicado: (2017)

Genetics of Non-Alcoholic Fatty Liver and Cardiovascular Disease: Implications for Therapy?
por: Chandrasekharan, Karthik, et al.
Publicado: (2020)

Benefits of the Therapy With Abexol in Patients With Non-Alcoholic Fatty Liver Disease
por: Fernandez-Travieso, Julio Cesar, et al.
Publicado: (2020)

Therapies for non-alcoholic fatty liver disease: A 2022 update
por: Shen, Katie, et al.
Publicado: (2022)

Role of Hepatokines in Non-alcoholic Fatty Liver Disease
por: Ke, Yini, et al.
Publicado: (2019)

The Role of Notch Signaling Pathway in Non-Alcoholic Fatty Liver Disease
por: Xu, Hao, et al.
Publicado: (2021)

Treatment of non-alcoholic fatty liver disease
por: Tolman, Keith G, et al.
Publicado: (2007)

Pathogenesis of non-alcoholic fatty liver disease
por: Dowman, J. K., et al.
Publicado: (2010)

Autophagy and Non-Alcoholic Fatty Liver Disease
por: Lavallard, Vanessa J., et al.
Publicado: (2014)

Non-Alcoholic Fatty Liver Disease in Children
por: SINGER, CRISTINA, et al.
Publicado: (2014)

Pathophysiology of Non Alcoholic Fatty Liver Disease
por: Petta, Salvatore, et al.
Publicado: (2016)

Pediatric Non-Alcoholic Fatty Liver Disease
por: Delvin, Edgard, et al.
Publicado: (2015)

Iron and non-alcoholic fatty liver disease
por: Britton, Laurence J, et al.
Publicado: (2016)

Apoptosis and non-alcoholic fatty liver diseases
por: Kanda, Tatsuo, et al.
Publicado: (2018)

Pediatric Non-Alcoholic Fatty Liver Disease
por: Bush, Haley, et al.
Publicado: (2017)

Non-alcoholic fatty liver disease and diabetes
por: Hazlehurst, Jonathan M., et al.
Publicado: (2016)

Hypoxia and Non-alcoholic Fatty Liver Disease
por: Isaza, Stephania C., et al.
Publicado: (2020)

Lipidomics in non-alcoholic fatty liver disease
por: Kartsoli, Sofia, et al.
Publicado: (2020)

Endotoxins and Non-Alcoholic Fatty Liver Disease
por: Kessoku, Takaomi, et al.
Publicado: (2021)

Pathology of non-alcoholic fatty liver disease
por: Cataldo, Ivana, et al.
Publicado: (2021)

Platelets in Non-alcoholic Fatty Liver Disease
por: Dalbeni, Andrea, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f4m3ats6hkp09cvgfiu5ne0ill